KR20230154177A - 림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물 - Google Patents
림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물 Download PDFInfo
- Publication number
- KR20230154177A KR20230154177A KR1020237027718A KR20237027718A KR20230154177A KR 20230154177 A KR20230154177 A KR 20230154177A KR 1020237027718 A KR1020237027718 A KR 1020237027718A KR 20237027718 A KR20237027718 A KR 20237027718A KR 20230154177 A KR20230154177 A KR 20230154177A
- Authority
- KR
- South Korea
- Prior art keywords
- fibroblasts
- cells
- adm
- pharmaceutical composition
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 426
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 96
- 210000004027 cell Anatomy 0.000 claims abstract description 334
- 230000014509 gene expression Effects 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 78
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 77
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 77
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 77
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 claims abstract description 60
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 claims abstract description 56
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 50
- 230000004761 fibrosis Effects 0.000 claims abstract description 50
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims abstract description 49
- 230000035168 lymphangiogenesis Effects 0.000 claims abstract description 43
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 claims abstract description 16
- 208000019693 Lung disease Diseases 0.000 claims abstract description 14
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 230000013632 homeostatic process Effects 0.000 claims abstract description 11
- 150000002632 lipids Chemical class 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- 230000037451 immune surveillance Effects 0.000 claims abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 2
- 210000004072 lung Anatomy 0.000 claims description 172
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 61
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 41
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 210000002216 heart Anatomy 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 19
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 13
- 101150097704 HHEX gene Proteins 0.000 claims description 6
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 101150054360 ADM gene Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000007972 injectable composition Substances 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 abstract description 87
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract description 43
- 206010053159 Organ failure Diseases 0.000 abstract description 10
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 5
- 239000000835 fiber Substances 0.000 abstract description 4
- 210000003969 blast cell Anatomy 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 102000004379 Adrenomedullin Human genes 0.000 description 142
- 101800004616 Adrenomedullin Proteins 0.000 description 142
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 142
- 102100040247 Tumor necrosis factor Human genes 0.000 description 75
- 210000001519 tissue Anatomy 0.000 description 66
- 210000001054 cardiac fibroblast Anatomy 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 241000700159 Rattus Species 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 37
- 210000000056 organ Anatomy 0.000 description 37
- 210000001365 lymphatic vessel Anatomy 0.000 description 36
- 239000002609 medium Substances 0.000 description 35
- 238000011282 treatment Methods 0.000 description 35
- 239000000523 sample Substances 0.000 description 34
- 239000000203 mixture Substances 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 30
- 238000000684 flow cytometry Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 238000002054 transplantation Methods 0.000 description 25
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 24
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 238000010586 diagram Methods 0.000 description 20
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 230000003176 fibrotic effect Effects 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000000492 lymphangiogenic effect Effects 0.000 description 15
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108010014173 Factor X Proteins 0.000 description 13
- 229940012426 factor x Drugs 0.000 description 13
- 206010007558 Cardiac failure chronic Diseases 0.000 description 12
- 210000001778 pluripotent stem cell Anatomy 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000005003 heart tissue Anatomy 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001000 micrograph Methods 0.000 description 10
- 108010006654 Bleomycin Proteins 0.000 description 9
- 229960001561 bleomycin Drugs 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011158 quantitative evaluation Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 108010007093 dispase Proteins 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000011201 multiple comparisons test Methods 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 101100215371 Homo sapiens ACTB gene Proteins 0.000 description 5
- 101100001051 Mus musculus Adm gene Proteins 0.000 description 5
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 102100037265 Podoplanin Human genes 0.000 description 5
- 101710118150 Podoplanin Proteins 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 102000046663 human ADM Human genes 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 101000742595 Mus musculus Vascular endothelial growth factor C Proteins 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 102000008790 VE-cadherin Human genes 0.000 description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 230000001745 anti-biotin effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 108010018828 cadherin 5 Proteins 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 239000011325 microbead Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010052014 Liberase Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009798 acute exacerbation Effects 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 102000057807 human HHEX Human genes 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229940028444 muse Drugs 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000012335 pathological evaluation Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 208000026062 Tissue disease Diseases 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 2
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000013424 sirius red staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229940123977 Lysophosphatidic acid receptor antagonist Drugs 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 1
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003994 anesthetic gas Substances 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008473 connective tissue growth Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000008274 immunosurveillance mechanism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034018 | 2021-03-04 | ||
| JP2021034016 | 2021-03-04 | ||
| JPJP-P-2021-034016 | 2021-03-04 | ||
| JPJP-P-2021-034018 | 2021-03-04 | ||
| PCT/JP2022/009205 WO2022186349A1 (ja) | 2021-03-04 | 2022-03-03 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230154177A true KR20230154177A (ko) | 2023-11-07 |
Family
ID=83155368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237027718A Pending KR20230154177A (ko) | 2021-03-04 | 2022-03-03 | 림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240148795A1 (https=) |
| EP (1) | EP4302771A4 (https=) |
| JP (2) | JP7233147B2 (https=) |
| KR (1) | KR20230154177A (https=) |
| AU (1) | AU2022231584A1 (https=) |
| CA (1) | CA3211113A1 (https=) |
| IL (1) | IL305069A (https=) |
| WO (1) | WO2022186349A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024101947A1 (ko) | 2022-11-11 | 2024-05-16 | 주식회사 엘지에너지솔루션 | 음극 활물질, 이를 포함하는 음극, 이를 포함하는 이차전지 및 음극 활물질의 제조방법 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240316113A1 (en) * | 2021-09-08 | 2024-09-26 | Metcela Inc. | Fibroblast-containing pharmaceutical composition for treating kidney disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020045547A1 (ja) | 2018-08-29 | 2020-03-05 | 株式会社メトセラ | 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102407387B1 (ko) * | 2017-02-24 | 2022-06-10 | 가부시키가이샤 메토세라 | 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 |
| US20240316113A1 (en) * | 2021-09-08 | 2024-09-26 | Metcela Inc. | Fibroblast-containing pharmaceutical composition for treating kidney disease |
-
2022
- 2022-03-03 CA CA3211113A patent/CA3211113A1/en active Pending
- 2022-03-03 AU AU2022231584A patent/AU2022231584A1/en active Pending
- 2022-03-03 KR KR1020237027718A patent/KR20230154177A/ko active Pending
- 2022-03-03 IL IL305069A patent/IL305069A/en unknown
- 2022-03-03 WO PCT/JP2022/009205 patent/WO2022186349A1/ja not_active Ceased
- 2022-03-03 EP EP22763401.1A patent/EP4302771A4/en active Pending
- 2022-03-03 JP JP2022539639A patent/JP7233147B2/ja active Active
- 2022-03-03 US US18/548,803 patent/US20240148795A1/en active Pending
-
2023
- 2023-02-14 JP JP2023020860A patent/JP2023058660A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020045547A1 (ja) | 2018-08-29 | 2020-03-05 | 株式会社メトセラ | 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団 |
Non-Patent Citations (17)
| Title |
|---|
| [비특허문헌 1] Circulation. 2016;133: 1484-1497 |
| [비특허문헌 10] Lymphat Res Biol., 2009;7:197-203 |
| [비특허문헌 11] Lymphat Res Biol., 2014;12:238-250 |
| [비특허문헌 12] Blood, 2012;119:5931-5942 |
| [비특허문헌 13] Lymphat Res Biol., 2010;8:199-207 |
| [비특허문헌 14] Am J Physiol - Heart Circ Physiol., 2008;295:2113-2127 |
| [비특허문헌 15] PLoS One., 2020;15:e0237810 |
| [비특허문헌 16] Pulm Pharmacol Ther., 2012 Aug;25:281-285 |
| [비특허문헌 17] Stem Cells Transl Med. 2017;6(10):1905-1916 |
| [비특허문헌 2] Bull N Y Acad Med., 1938; 14: 231-251 |
| [비특허문헌 3] Am J Physiol Endocrinol Metab., 2009; 296: E1183-E1194 |
| [비특허문헌 4] Front Immunol., 2016; 7: 613 |
| [비특허문헌 5] Peptides, 2008; 29: 2243-2249 |
| [비특허문헌 6] J Cardiovasc Pharmacol., 2010; 56: 413-419 |
| [비특허문헌 7] Nat Commun., 2018; 9; Article number 2704 |
| [비특허문헌 8] Ann Intern Med., 2020;172(9):629-63 |
| [비특허문헌 9] Semin Respir Crit Care Med., 2006;27:600-612 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024101947A1 (ko) | 2022-11-11 | 2024-05-16 | 주식회사 엘지에너지솔루션 | 음극 활물질, 이를 포함하는 음극, 이를 포함하는 이차전지 및 음극 활물질의 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022186349A1 (ja) | 2022-09-09 |
| JP2023058660A (ja) | 2023-04-25 |
| EP4302771A1 (en) | 2024-01-10 |
| AU2022231584A1 (en) | 2023-09-07 |
| IL305069A (en) | 2023-10-01 |
| US20240148795A1 (en) | 2024-05-09 |
| JP7233147B2 (ja) | 2023-03-06 |
| EP4302771A4 (en) | 2025-04-02 |
| CA3211113A1 (en) | 2022-09-09 |
| JPWO2022186349A1 (https=) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5968442B2 (ja) | 心筋梗塞の修復再生を誘導する多能性幹細胞 | |
| Yano et al. | Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair | |
| KR102146815B1 (ko) | Hmgb1 단편을 이용한 신규 심근경색의 치료법 | |
| JP7428389B2 (ja) | 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団 | |
| JP7353652B2 (ja) | 生体移植用細胞シート及びその製造方法 | |
| CN113574167B (zh) | 利用混合物4f增加干细胞生物学活性的组合物 | |
| WO2023242605A1 (en) | Extracellular vesicles for use in therapy | |
| KR20230154177A (ko) | 림프관 신생촉진인자 발현 섬유아세포 및 이를 포함하는의약 조성물 | |
| KR102793810B1 (ko) | 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물 | |
| JP2023001294A (ja) | 臓器線維症の予防または治療剤 | |
| CN117120063A (zh) | 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物 | |
| KR20190141234A (ko) | 간엽계 줄기세포의 제조 방법, 간엽계 줄기세포의 치료 효과 마커, 치료 효과 판정 방법, 및 간엽계 줄기세포를 포함하는 세포 제제 | |
| US20080317720A1 (en) | Fat-Derived Progenitor Cell and Use Thereof | |
| Suzuki et al. | The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment | |
| WO2021060460A1 (ja) | 生体組織損傷の修復剤の製造方法および生体組織損傷の修復剤 | |
| WO2003082305A1 (en) | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells | |
| Wang et al. | Role of axonal guidance factor netrin-1 in human placental vascular growth | |
| JP7193849B2 (ja) | 虚血組織に集積するエクソソームおよびその製造方法 | |
| KR101789475B1 (ko) | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 골다공증 예방 또는 치료용 조성물 | |
| WO2022138955A1 (ja) | 動脈解離の治療剤 | |
| KR20170091882A (ko) | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 골다공증 예방 또는 치료용 조성물 | |
| CN120857934A (zh) | 一种用于预防和/或治疗与脑血流减少相关的疾病或状态的药物 | |
| JP2022158688A (ja) | 遺伝子発現制御剤 | |
| Gupte | Pluripotent Hematopoietic Stem Cells Augment α-Adrenergic Receptor-Mediated 1 Contraction of Pulmonary Artery and Contribute to the Pathogenesis of Pulmonary 2 Hypertension 3 | |
| WO2006103770A1 (ja) | 血管新生制御方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230816 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20241030 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250221 Comment text: Request for Examination of Application |